The latest price trend and purchasing channel reference of inavolisib

Inavolisib (trade name Itovebi) is a highly selective PI3Kα inhibitor, mainly used to treat HR+/HER2- breast cancer patients, especially those with PIK3CA gene mutations and resistant to endocrine therapy. The drug controls tumor growth by inhibiting the PI3K signaling pathway and blocking the proliferation and survival signals of tumor cells. The precise targeting properties of inalised make it of significant clinical significance in the treatment of refractory breast cancer, providing a new treatment option for high-risk patients.

In terms of price, inalise has been on the market for a short time in China and is not included in medical insurance, so the price is relatively high. The current common specifications are 3mg 7 tablets 4 boards or 9mg 7 tablets 4 boards. Each box sells for about 30,000 yuan. In overseas markets, the US version of the original drug may cost more than 200,000 yuan equivalent to RMB. Price differences are mainly affected by factors such as regional pricing strategies, medical policies, and import costs.

In terms of purchasing channels, Inalise is a prescription drug and must be used by patients under the guidance of a professional doctor. In China, formal access channels include specialty drug pharmacies, imported drug sales platforms, and authorized hospital pharmacies. Due to the high price of drugs, patients should understand the price information and payment methods in detail before purchasing, and plan their medication plan based on their own financial situation and medical insurance policies. At the same time, doctors will formulate individualized treatment plans based on the patient's PIK3CA genetic status and physical condition.

In the future, with the promotion and clinical application of inalisate in domestic and foreign markets, generic versions may appear, which is expected to reduce prices and improve accessibility to a certain extent. Patients need to regularly monitor blood sugar and liver and kidney function during use, because the drug may cause adverse reactions such as hyperglycemia. Overall, inalise provides a precise targeted treatment option for specific breast cancer patients, but the high price and strict medication conditions require patients to scientifically manage medication and strictly follow doctor's instructions.

Reference link:https://www.drugs.com